Key result
Third-generation dihydropyridine calcium antagonists, particularly lercanidipine and lacidipine, provide effective blood pressure reduction with a lower incidence of adverse effects like peripheral edema compared to older agents.
Answers are grounded in this paper and cite their sources.
This review highlights the pharmacokinetic and pharmacodynamic advantages of third-generation dihydropyridine calcium antagonists, emphasizing lercanidipine's efficacy and reduced side effect profile in hypertension management.
The majority of modern preparations of calcium antagonists (CA) concern to derivatives dihydropiridine which prototype is nifedipine. For today CA is more than ten preparations with various clinical application, mainly in cardiology. The purpose of the given work the review pharmacokinetics and pharmacodynamics properties of III generation of dihydropiridines, used for treatment of an arterial hypertension. The most known representative of III generation is amlodipine. Last years in the world popularity lacidipine and lercanidipine grows as well.
No takes yet. Share an insight, caveat, or question.
Bronskaya et al. (2005) conducted a review in Arterial hypertension. Third-generation dihydropyridine calcium antagonists (amlodipine, lacidipine, lercanidipine) was evaluated. Third-generation dihydropyridine calcium antagonists, particularly lercanidipine and lacidipine, provide effective blood pressure reduction with a lower incidence of adverse effects like peripheral edema compared to older agents.
Synapse has enriched 10 related papers. Consider them for comparative context: